Johnson & Johnson
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3042% above fair value
$270.56−2.64 (-0.97%)
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson MedTech — Research and development expense by Year
MedTech — Research and development expense ($M) ($M)
Johnson & Johnson MedTech — Research and development expense: $2,838M in FY2025, down 23.4% from a year earlier.
Latest, FY2025
2,838
Period ended Dec 28, 2025
Change on a year earlier
-23.4%
3,703 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MedTech — Research and development expense ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 2,838 | -23.4% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 3,703 | +18.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 3,122 | +25.2% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 2,493 | – | Form 10-K (filed 2025-02-13) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson MedTech — Research and development expense ($M), annual FY2022–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg-rd-mt
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.